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The aim of this study was to ascertain if oestrogen receptor (ER) status predicts for pathological complete response (pCR) to
neoadjuvant chemotherapy in operable breast cancer, and the effects of pCR on survival. Using a single-institution database, 435
patients were identified, who received neoadjuvant chemotherapy for operable breast cancer and were eligible for the analysis.
Patients whose tumours were ER negative were more likely to achieve a pCR than patients who were ER positive (21.6 vs 8.1%,
Po0.001). Owing to a strong correlation between ER status and grade, these variables were not shown to be independent
predictors of pCR. Overall survival (OS) was better in those patients who achieved a pCR compared to those who did not (5-year
OS 91 vs 73%; P¼0.02). This was still the case when only patients with ER-negative tumours were examined (5-year OS 90 vs 52%,
P¼0.005), but not in the subset of patients with ER-positive tumours (5-year OS 93 vs 79%; P¼0.3). Therefore, patients with ER-
negative tumours were found to be more likely to achieve a pCR to neoadjuvant chemotherapy than those with ER-positive tumours,
and pathological response did not have prognostic significance in patients with ER-positive tumours.
British Journal of Cancer (2004) 91, 2012–2017. doi:10.1038/sj.bjc.6602235 www.bjcancer.com
Published online 23 November 2004
& 2004 Cancer Research UK
Keywords: neoadjuvant chemotherapy; oestrogen receptor; pathological response
                                         
Neoadjuvant chemotherapy is increasingly being used in the
management of patients with large operable and locally advanced
breast cancers. This treatment is administered in the hope that
downstaging might avoid mastectomy, as an in vivo measure of
chemosensitivity, and to enable systemic treatment of occult
micrometastatic disease (Smith and Lipton, 2001). Randomised
trials comparing pre-operative and post-operative adjuvant
chemotherapy in early breast cancer show similar rates of local
control and overall survival (OS), but the mastectomy rate is lower
with the pre-operative approach (Scholl et al, 1994; Powles et al,
1995; Fisher et al, 1998).
Existing studies show that the patients who benefit the most
from neoadjuvant chemotherapy are those who achieve a
pathological complete response (pCR) with no residual micro-
scopic tumour. This is relatively uncommon, occurring in only 3–
16% of patients (Powles et al, 1995; Bonadonna et al, 1998; Fisher
et al, 1998; Buzdar et al, 1999; Kuerer et al, 1999; van der Hage et al,
2001), but it is important because patients achieving a pCR have a
substantially improved disease-free survival (DFS) and OS
compared to those with pathological evidence of residual cancer
(Bonadonna et al, 1998; Fisher et al, 1998; Kuerer et al, 1999). In
order to identify those most likely to achieve benefit from
neoadjuvant chemotherapy, it would be useful to be able to
identify predictors of pCR prior to commencing treatment.
Recent data, published in abstract form, have suggested that
negative oestrogen receptor (ER) status may be predictive of pCR
in patients receiving neoadjuvant chemotherapy for operable and
locally advanced breast cancer (Buzdar et al, 2003; Euler and
Tulusan, 2003). We have tested this hypothesis in a retrospective
analysis of ER status as a variable to predict pCR in the breast and
axilla in patients receiving neoadjuvant chemotherapy at the Royal
Marsden Hospital.
PATIENTS AND METHODS
Patient selection
A sequential and prospectively maintained database was retro-
spectively searched for patients who received neoadjuvant
chemotherapy for primary operable breast carcinoma. Patients
with locally advanced disease (defined as inoperable by the
Haagensen criteria (Haagensen and Stout, 1943)) or inflammatory
breast cancer were excluded from this analysis. Patients were only
eligible if the diagnosis had been confirmed histologically (by core
biopsy) prior to commencement of chemotherapy, and they had
undergone surgery following chemotherapy. Metastatic disease
was excluded using chest X-ray, complete blood count, and
biochemical liver and bone profiles; further investigations were
only carried out if clinically indicated. Patient characteristics
including clinical stage, menopausal status, tumour grade, ER
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lstatus, type of chemotherapy and pathological response in breast
and axilla were recorded. Patients who received neoadjuvant
chemotherapy between 19 February 1985 and 18 February 2003
were eligible for this analysis. Data available up to 30 September
2003 were used.
Treatment
Neoadjuvant chemotherapy included: (1) anthracycline-based
regimens using epirubicin 60mgm
 2 or doxorubicin 60mgm
 2;
(2) cyclophosphamide (CMF) 100mg orally on days 1–14,
methotrexate 30mgm
 2 on days 1 and 8, 5-fluorouracil 1gm
 2
on days 1 and 8; and occasionally (3) mitoxantrone-containing
regimens (up to 11mgm
 2). Six cycles of treatment were planned,
given once every 3 weeks, although some of the early infusional
regimens involved eight cycles of treatment. Response after each
cycle was evaluated by clinical measurement of the two largest
diameters, and graded according to standard WHO criteria. All
chemotherapy was delivered prior to local therapy, post-operative
adjuvant chemotherapy was not given.
Following chemotherapy, all patients included in this analysis
underwent surgery (conservative or mastectomy). Up until 1995,
patients achieving a clinical complete response had been offered
the option of not having surgery. However, this practice was
stopped following an audit, which suggested a high local
recurrence rate; these patients were excluded from the current
analysis and have been reported elsewhere (Ring et al, 2003). All
patients undergoing breast-conserving surgery were given breast
radiotherapy. The range of doses given to the breast was 46–50Gy,
with boosts to tumour bed at 11.1–17.5Gy. Our policy was also to
give radiotherapy to the axilla if surgically untreated (dose range
46–50Gy), and to the supraclavicular fossa (dose range 46–50Gy),
where axillary node status was positive or unknown. Radiotherapy
was also given to patients with involved axillary nodes after
mastectomy. Tamoxifen (20mg) was given to most patients within
the context of clinical trials or according to standard practice at the
time.
Follow-up
Patients were reviewed after each cycle of chemotherapy for
clinical response. Following surgery or radiotherapy, they were
reviewed every 3 months for 2 years, then 6 monthly until 5 years.
Thereafter, they were assessed clinically and with mammography
annually.
Immunohistochemical analysis of ER status
Oestrogen receptor status was assessed on the diagnostic core
biopsy specimen prior to the commencement of chemotherapy.
For 254 of the final 382 patients for whom ER status was available,
this was ascertained at the time of initial treatment. For the
remainder, paraffin blocks were acquired from the archives and ER
status ascertained for the purposes of this analysis.
All ER assays were conducted by a laboratory, which
participated in the relevant UK National External Quality
Assessment Scheme throughout this period. Until 1992 ER was
measured by multiple-point ligand-binding/dextran-coated char-
coal assay (DCC), with values being obtained by Scatchard plot
analysis. Between 1993 and December 1994, ER was measured by
enzyme immunoassay (EIA) using kits (Abbott Diagnostics,
Chicago, IL, USA). From 1995 onwards, an immunocytochemical
assay was used with either the DAKO 1D5 or Novocastra 6F11
antibodies (Dako, Cambridge, UK and Novocastra Laboratories
Ltd, Newcastle upon Tyne, UK). Antigen retrieval, incubation with
primary and secondary antibodies, and development using
streptavidin ABC-horseradish peroxidase were performed as
described previously (Detre et al, 1999). From March 2003, this
process was performed in a semiautomated manner using the
Ventana Benchmarkt system (Ventana Medical Sytems, Illkirch,
France). Progesterone receptor and HER2 status were only
available for a few patients and were therefore not included in
this analysis.
In both DCC and EIA assays, values of X10fmolmg
 1 protein
were considered as positive. When slides were analysed by
immunohistochemistry, a score was assigned which estimated
the proportion of positive-staining tumour cells (0, 1, 10 or 100%),
and the intensity of staining (0, none; 1, weak; 2, intermediate; 3,
strong). Tumours were defined as positive if ER staining of any
intensity was seen in 10% or more of cells.
Histological examination of tissue
A pCR was defined as no residual invasive disease in the breast or
regional lymph nodes. Where there was only residual DCIS, this
was included in the pCR category.
Statistical methods
The influence of baseline characteristics on the likelihood of
achieving a pCR was tested in a univariate analysis by means of the
w
2 test or Fisher’s exact test. The independent significance of these
variables was assessed in a multivariate logistic regression analysis
using a step-up procedure. The odds ratios of a pCR were
calculated from the final model. Overall survival and recurrence-
free survival were measured from the date of first treatment until
death or recurrence, respectively; deaths without recurrence were
censored in the recurrence-free survival analysis. Survival curves
were calculated by the Kaplan–Meier method and differences were
assessed by the log-rank statistic (Kaplan and Meier, 1958; Peto
et al, 1977).
RESULTS
Pathological complete response in the breast
Between 19 February 1985 and 18 February 2003, 439 patients were
recorded as having surgery following neo-adjuvant chemotherapy
for primary operable breast cancer. Pathology was not available in
four cases, leaving 435 for analysis. Overall, 165 (38%) of the
patients underwent conservative surgery and 270 (62%) underwent
mastectomy. In all, 33 (8%) of the patients had no residual invasive
or noninvasive disease present after chemotherapy and 19 (4%)
had residual DCIS only (Table 1). Both of these groups were
included in the pCR category, making the overall pCR rate 12%. A
further five patients had a pCR in the breast, but had residual
axillary lymph node involvement and therefore were not included
in the pCR category. Of those women with ER-positive tumours, 66
were postmenopausal and six were aged over 55 and had
undergone a hysterectomy. Three of these 72 women (4%)
achieved a pCR following neoadjuvant chemotherapy.
On univariate analysis, factors associated with a pCR were ER
status (Po0.001), primary tumour size by T-stage (P¼0.01),
tumour grade (Po0.001) and anthracycline vs nonanthracycline
chemotherapy (P¼0.003) (Table 1). Differences in pCR rate
according to menopausal status and whether or not infusional
chemotherapy was used were not statistically significant (Table 1).
Tumour type was not routinely assessed on core biopsy; so this
parameter was not included in the analysis.
A multivariate analysis was performed using the variables
menopausal status, ER status, grade (I and II vs III) and
anthracycline vs other chemotherapy. Oestrogen receptor status
and grade were found to be highly correlated with 72% of ER-
negative tumours also being grade 3, compared with 40% of ER-
positive tumours. Owing to this correlation, ER status and tumour
grade were not found to be independently significant prognostic
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lindicators of pCR. However, when a statistical model was used
where grade was excluded from the analysis, ER status was the
main factor predicting pCR (P¼0.001). After adjusting for this,
the chemotherapy regimen has an additional marginal significance
(P¼0.02), with patients receiving anthracycline-based chemother-
apy more likely to achieve a pCR than those receiving other
regimens (Table 2).
Survival
At a median follow-up of 53 months, the 5-year OS in all patients
was 75% and the 5-year DFS 62%. A pCR following neoadjuvant
chemotherapy was associated with improved survival (5-year OS
91 vs 73%; P¼0.02, Figure 1). There was a trend to improvement
in DFS in patients achieving a pCR, but this did not reach
statistically significant values (P¼0.07, Figure 2). Pathological
complete response did not influence the rate of isolated local
recurrences (P¼0.5, data not shown). Negative ER status was
associated with a worse OS, with a 5-year OS of 60% in ER-negative
patients compared with 80% in ER-positive patients (P¼0.0001,
Figure 3). Disease-free survival and isolated local recurrence rates
were also inferior in patients with ER-negative tumours
(P¼0.0001 and 0.01, respectively, Figures 4 and 5).
When only those patients with ER-negative tumours were
examined, it was confirmed that those patients who achieved a
pCR had an improved DFS and OS compared with those with
residual disease (5-year DFS 73 vs 37%; P¼0.001; 5-year OS 90 vs
52%; P¼0.005, Figures 6A and 7A). However, this was not the case
in patients with ER-positive tumours, where there were no
significant differences in either DFS or OS between those who
achieved a pCR and those who did not (5-year DFS 73 vs 67%;
P¼1.0; 5-year OS 93 vs 79%; P¼0.3, Figures 6B and 7B). In
addition, in those patients with ER-negative tumours who achieved
a pCR, DFS and OS were at least comparable with those of patients
with ER-positive tumours who achieved a pCR (5-year DFS 79 vs
73%; P¼0.03) and those who did not (5-year DFS 79 vs 67%;
P¼0.2).
Table 1 Univariate analysis of factors predicting pCR in the breast
following neoadjuvant chemotherapy
Baseline factor Total pCR Significance (P)
Total 435 52 12.00%
ER
Positive 271 22 8.10% o0.001
Negative 111 24 21.60%
Unknown 53 6 11.30%
Menopausal status
Pre-meno 254 35 13.80% 0.4
Peri 39 5 12.80%
Post 109 9 8.30%
Hyst 33 3 9.10%
Clinical tumour size
T-1 5 2 40% 0.01
T-2 235 34 14.50%
T-3 168 14 8.30%
T-4 20 1 5.00%
Clinical nodes
Not palpable 240 31 12.90% 0.5
Palpable 195 21 10.80%
Grade
I 31 1 3.20% o0.001
II 169 4 2.40%
III 179 28 15.60%
Not classifiable 56 19 33.90%
Chemotherapy
Anthracycline 359 50 13.90% 0.003
Nonanthracycline 76 2 2.60%
Infusional 89 15 16.90% 0.1
Conventional 346 37 10.70%
Table 2 Multivariate analysis of factors predicting pCR in the breast
following neoadjuvant chemotherapy, using a model excluding grade from
the analysis
Factor
Odds
ratio 95% CI
Significance
(P)
ER negative vs ER positive 3.08 (1.63, 5.81) 0.001
Anthracycline vs other chemotherapy 10.11 (1.37, 74.83) 0.02
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Figure 1 Overall survival according to pathological response (all
patients).
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Figure 2 Disease-free survival according to pathological response (all
patients).
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lDISCUSSION
This is a large single-centre analysis, with pathological response
assessed by a single group of pathologists. It demonstrates
that patients whose tumours are ER negative are more likely to
achieve a pCR following neoadjuvant chemotherapy than
those with ER-positive tumours. In vitro assays and clinical
studies in the metastatic setting have shown that ER-negative
breast cancers are more sensitive to chemotherapy than
ER-positive tumours (Kaufmann et al, 1980; Rosner et al, 1989).
Similarly, the Early Breast Cancer Trialists’ Collaborative Group
has shown that, with the use of adjuvant polychemotherapy,
proportional reductions in recurrence are significantly greater for
women with ER-poor tumours compared with those with ER-
positive disease (Early Breast Cancer Trialists’ Collaborative
Group, 1998).
Previous studies have shown that ER-negative tumours are likely
to have better clinical (as opposed to pathological) responses
than ER-positive tumours (Bonadonna et al, 1990; Mauriac et al,
1991; MacGrogan et al, 1996). Colleoni et al (2000b) found a
significantly higher clinical response rate in patients receiving
neoadjuvant chemotherapy, in whose tumours ER and PgR
were absent, compared to those where ER and/or PgR were
expressed (82 vs 57%; P¼0.03). However, the measurement of
clinical responses is to an extent subjective, and the assessment of
pathological response may be more robust and reproducible.
Overall survival
Years
14 12 10 8 6 4 2 0
S
u
r
v
i
v
a
l
1.0
0.8
0.6
0.4
0.2
0.0
ER +ve (271)
ER −ve (111)
P = 0.0001
Figure 3 Overall survival according to ER status (all patients).
Isolated local recurrence
Years
14 12 10 8 6 4 2 0
L
o
c
a
l
 
r
e
c
u
r
r
e
n
c
e
 
f
r
e
e
1.0
0.8
0.6
0.4
0.2
0.0
ER +ve (271)
ER −ve (111)
P = 0.01
Figure 5 Isolated local recurrence rate according to ER status (all
patients).
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Figure 4 Disease-free survival according to ER status (all patients).
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Figure 6 Disease-free survival according to pathological response in
patients whose tumours are ER negative (A) and ER positive (B).
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lTherefore, it is an important finding that, in the same study,
at least on univariate analysis, pCR rates were also higher in the
ER- and PgR-absent group (23 vs 7%; P¼0.04; Colleoni et al,
2000b). Kuerer et al (1999) also found higher pCR rates in women
with ER-negative locally advanced breast cancers treated with
neoadjuvant chemotherapy (17 vs 3%; Po0.01, ER negative vs ER
positive). In this study, the effects of ER status were found to be
independent of initial tumour size on multivariate analysis,
although ER status was not demonstrated to predict pCR
independently of tumour grade.
In our study, on univariate analysis, ER-negative status
was again shown to predict for pCR, with a pCR rate of 22%
compared with 8% in ER-positive tumours (Po0.001). However,
the strong correlation between ER status and tumour grade
meant that neither could be demonstrated to be an independent
prognostic indicator of pCR. Poor nuclear grade is recognised
to predict pCR in the neoadjuvant setting (Fisher et al, 2002).
There are, however, practical issues in getting reproducible
measurements of tumour grade from the small amount of
tissue acquired at core biopsy, and previous studies have
shown that tumour grade assessed on core biopsy may not be
representative of the final surgical specimen (Connor et al, 2002;
Harris et al, 2003). In contrast, ER status assessed on core biopsy
shows good concordance with the surgical specimen (Jacobs et al,
1998; Connor et al, 2002) and, when a statistical model excluding
grade was used in this analysis, ER status was the main factor
predicting pCR.
This is an important consideration when interpreting trials of
neoadjuvant chemotherapy. The ER status of the trial population
should be carefully examined. High pCR rates in unrandomised
trials and differences in pCR rates between treatments in
randomised trials could be explained by high proportions of ER-
negative patients and imbalances in ER status between treatment
arms, respectively.
It should be recognised that the cutoff used to define ER-
negative status differs between studies in this area. In our analysis,
in common with historical practice, patients were classified as ER
positive (X10fmolmg
 1 cytosol protein or X10% of positive
cells) or ER negative (p10fmolmg
 1 cytosol protein or o10% of
positive cells). However, the study published by Colleoni et al
(2000b) defined an ER-absent group as one with 0% cells positive
and ER positive when X1% of cells stained positive. Similarly, the
IBCSG has previously defined three groups on the basis of ER
content: ER absent, ER low (1–9fmolmg
 1 cytosol protein) and
ER positive (X10fmolmg
 1 cytosol) (Colleoni et al, 2000a). This
was based on data showing a better prognosis for tumours with as
few as 1% of cells staining positive when treated with tamoxifen
(Harvey et al, 1999).
The survival data presented in this analysis concur with
previous studies in that overall patients who are ER positive
and those who achieve a pCR following neoadjuvant chemotherapy
have a better prognosis. However, an important additional finding
is that, when patients with ER-negative tumours achieve a
pCR, their survival is comparable with that of ER-positive
patients. This is despite the fact that overall patients with ER-
negative tumours have a worse prognosis than those with
ER-positive tumours. Therefore, in patients with ER-negative
tumours, the degree of pathological response following neoadju-
vant chemotherapy may provide important prognostic informa-
tion. This may have practical implications for subsequent
treatment and follow-up.
A second novel finding was that, although patients with
ER-negative tumours achieving a pCR had an improved prognosis,
this was not the case in patients who had ER-positive tumours.
The latter had similar DFS and OS regardless of pathological
response. This represents a potentially important finding which, if
corroborated, would imply that the surrogate outcome measure
pCR, used in many neoadjuvant chemotherapy trials, may not be a
valid predictor of final outcome in patients with ER-positive
tumours.
As with all retrospective studies, there are limitations to this
analysis and the results should be interpreted with caution. Only
small numbers of patients are included and in particular very few
patients with ER-positive tumours achieved a pCR meaning that
the survival data are difficult to interpret. Although pathological
assessment was undertaken at a single institution with protocols
that adhered to National guidelines, there is likely to have been
variability over the years in ascertainment of histological grade, ER
status and the number of tumour blocks examined. In addition, ER
status was not known for 53 of the 435 patients, and a population
of patients who did not undergo surgery was excluded from the
analysis, introducing further bias.
If the results of this small retrospective analysis are replicated in
future prospective studies, there may be important implications
not only in terms of prediction of response and survival, but also
in terms of choice of neoadjuvant therapy. The relatively low pCR
rate following neoadjuvant chemotherapy in those patients with
ER-positive tumours might suggest that alternative approaches
such as primary surgery or hormonal therapy may be preferable.
In particular, the low pCR rate in postmenopausal women with ER-
positive tumours may mean that primary aromatase inhibitor
treatment is an attractive option.
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Figure 7 Overall survival according to pathological response in patients
whose tumours are ER negative (A) and ER positive (B).
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